Children with Down syndrome (DS) are at a 20-fold increased risk for acute lymphoblastic leukemia (DS-ALL). Although the etiology of this higher risk of developing leukemia remains largely unclear, the recent identification of CRLF2 (cytokine receptor like factor 2) and JAK2 mutations and study of the effect of trisomy of Hmgn1 and Dyrk1a (dual-specificity tyrosine phosphorylation-regulated kinase 1A) on B-cell development have shed significant new light on the disease process. Here we focus on the clinical features, biology and genetics of ALL in children with DS. We review the unique characteristics of DS-ALL on both the clinical and molecular levels and discuss the differences in treatments and outcomes in ALL in children with DS compared with those without DS. The identification of new biological insights is expected to pave the way for novel targeted therapies.
CLINICAL FEATURES AND TREATMENT OF DS-ALL Down syndrome (DS) is one of the most common chromosomal disorders, occurring in~1 in 800 births annually in the United
States. DS is caused by trisomy for chromosome 21 (Hsa21) and is associated with several well-established morbidities including cardiac defects, growth anomalies, endocrinopathies, ophthalmologic disorders and learning disabilities. [1] [2] [3] [4] [5] Despite the fact that children with DS have a higher risk for malignant neoplasms, 6 the incidence of solid tumors in people with DS is actually lower compared with that in the population without DS, including all age groups. 7, 8 However, there is clear predominance of leukemia including both acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), which occur mostly in young patients. Moreover, children with DS are frequently born with transient myeloproliferative disorder, a preleukemia that is characterized by excessive growth of immature megakaryoblasts. In contrast to acute megakaryoblastic leukemia (AMKL) in children without DS, DS-AMKL blasts often coexpress megakaryocytic and erythroid markers, 9 perhaps owning to the unique presence of GATA1 mutations in the latter cells. 10 Unlike AMKL in children and adults without DS, DS-AMKL is highly curable with standard lowdose chemotherapy. [11] [12] [13] This increased drug sensitivity is likely due to altered cytidine deaminase levels that are a consequence of the GATA1 mutations. 14 There are also some unique features of ALL in children with DS. These include the predominance of Caucasians, 15 significant rarity of infant ALL 16, 17 and a paucity of T-cell ALL. [16] [17] [18] Moreover, favorable cytogenetics such as ETV6-RUNX1, double trisomy (trisomy of 4 and 10) and high hyperdiploidy, as well as unfavorable cytogenetics such as BCR-ABL1 and MLL rearrangements, are less common in DS-ALL than non-DS-ALL. [16] [17] [18] [19] In the recent International Ponte di Legno study, which analyzed retrospective data from 16 clinical trials, the majority of the DS subgroup (40.3%) had a normal karyotype (i.e. other than the constitutional trisomy 21), which is in marked contrast to the low incidence in non-DS children (6.9%). 17 Standard therapy is generally used for DS-ALL, but the unique toxicity profiles and higher relapse rate for patients with DS bring challenges. Table 1 summarizes the outcome of DS-ALL observed in studies published in the past decade. At least six different reports conclude that there is an inferior outcome for the cohort with DS. For example, the Ponte di Legno study, which analyzed data from 16 international trials, concluded that patients with DS-ALL had a higher 8-year cumulative incidence of relapse compared with the non-DS-ALL reference cohort from the Dutch Child Oncology Group and the Berlin-Frankfurt-Muenster study groups (26 ± 2% vs 15 ± 1%, P o0.0001). 17, 18 This study also found that age o6 years, white blood cell count o 10 × 10 9 /l and the presence of ETV6-RUNX1 were independent favorable prognostic factors for event-free survival (EFS), whereas age, ETV6-RUNX1 and high hyperdiploidy were associated with better relapse-free survival. Furthermore, the study found a higher 2-year incidence of treatment-related mortality in the group with DS (7 ± 1% vs 2 ± 1% in patients with DS or non-DS, respectively, P o0.001) that was associated with a lower EFS. Separately, the Nordic Society of Pediatric Hematology and Oncology ALL92 and ALL2000 protocols concurred that the 5-year EFS for patients with DS was poorer compared with those without DS. 20 These authors concluded that the physician's lack of protocol adherence and decreased doses of methotrexate and mercaptopurine during the maintenance phase may have contributed to the inferior outcome in DS patients. Indeed, the higher relapse rate may be a consequence of dose reduction, as suggested by the Ponte di Legno study. With respect to the toxicity issues, a recent Children's Oncology Group (COG) high-risk ALL study, AALL0232, which included prednisone or dexamethasone, vincristine, PEG-asparaginase and daunorubicin, and a standard-risk study, AALL0932, which included dexamethasone, vincristine and PEG-asparaginase, revealed excessive mortality during the induction phase in patients with DS. 21 After the addition of extensive supportive care guidelines and leucovorin rescue for intrathecal methotrexate, mortality improved with the AALL0932 protocol, but not in the AALL0232 protocol. Based on these studies, the three-drug combination is used during induction of DS-ALL patients enrolled on the successor COG high-risk protocol AALL1131. In contrast, the Ponte di Legno retrospective analysis found no difference in treatment-related mortality between the three-and four-drug induction, suggesting that there is no impact of anthracycline on treatment-related mortality. 17 Another important observation of the Ponte di Legno study was that treatment-related mortality in DS was seen in all phases of treatment, including maintenance therapy, which rarely leads to death in ALL patients without DS. 17 It is also widely recognized that patients with DS have a higher incidence of methotrexate toxicity, which is most commonly gastrointestinal. 22 Therefore, high-dose methotrexate is avoided or the dose is titrated in most protocols. 17 Although there is a concern about increased toxicity of certain ALL therapies in DS patients, the data are not consistent across studies. Overall though, it is clear that the outcome of DS-ALL patients is worse than that of the general pediatric population. The unique issues that face patients with DS-ALL and potential solutions are summarized in Table 2 .
Although hematopoietic stem cell transplantation remains a viable option for those with high-risk or relapsed ALL, the data on hematopoietic stem cell transplantation in patients with DS are limited and the role in relapsed patients with DS remains unclear. 23, 24 There are several novel targeted therapies, which may help to improve survival in this population including chimeric antigen receptor T cells, which have shown significant activities in adult and pediatric ALL. [25] [26] [27] [28] [29] Other immunomodulatory agents include blinatumomab, a CD19/CD3 bispecific antibody that redirects cytotoxic T cells to CD19-expressing leukemic cells. 30 This antibody, which has progressed through phase 1 and 2 studies and is currently in phase 3 in pediatric ALL, has been used in at least one patient with DS. 31 Other potential new therapies include those that target JAK2 or mTOR, whose pathways are activated in the majority of DS-ALL cases (see 'Genetics of DS-ALL'). Investigational agents that should be considered include JAK inhibitors, such as ruxolitinib and momelotinib, and mTOR inhibitors including temsirolimus and everolimus. [32] [33] [34] These new agents with novel mechanisms that show promise in B-ALL may be helpful in DS patients with refractory or relapsed disease, but unfortunately, patients with DS are excluded from many clinical trials for a concern of toxicity. Clinical trials in this population are encouraged.
GENETICS OF DS-ALL
Recent studies have provided key insights into other genetic contributions that have a role in the increased risk for and development of DS-ALL. These alterations include mutations in JAK2, NRAS and KRAS, mutations or overexpression of CRLF2 (cytokine receptor like factor 2) and trisomy 21 ( Figure 1 ). While the specific genes on Hsa21 that participate in B-ALL have been unclear, recent studies implicate HMGN1 (ref. 35 ) and DYRK1A (dual-specificity tyrosine phosphorylation-regulated kinase 1A). 36 Several other genetic events have been found in DS-ALL, including IKZF1 deletion, 37, 38 PAX5 deletion, 39, 40 ETV6-IGH rearrangement 41 and histone gene deletions. 42 Given this extensive list of genetic alterations involved in DS-ALL, it is not surprising that prior studies in human DS-ALL samples have emphasized the genetic heterogeneity of this subtype. 43 The complexity of DS-ALL is recapitulated in an animal model of DS-ALL, which required the combination of a JAK2 mutation, CRLF2 overexpression, Pax5 deficiency, Ikzf (Ikaros) loss and the mouse equivalent of trisomy 21 for disease. 35 In the following sections, we review the major genetic changes involved in DS-ALL and how these affect disease progression.
DRIVING EVENTS IN DS-ALL Alterations in CRLF2
Among the genetic abnormalities implicated in development of DS-ALL, aberrant expression of CRLF2 has been well characterized. CRLF2 is an important lymphoid signaling receptor, which complexes with interleukin-7 receptor subunit α (IL-7Rα) to form a heterodimeric receptor for thymic stromal lymphopoietin (TSLP). Overall, CRLF2 dysregulation is found in~10% of pediatric sporadic BCP-ALL, but in 60% of DS-ALL, indicating its role as a significant inciting factor in the development of the DS subtype. 44 This dysregulation occurs by different mechanisms, including chromosomal rearrangements and point mutations. Several groups discovered that CRLF2 is overexpressed or mutated in a subset of B-ALL cases that lack common translocations such as t (12;21) and t(1;19), particularly DS-ALL. 43, [45] [46] [47] Overexpression of CRLF2 is caused by both novel deletions of the pseudoautosomal region 1 (PAR1) of Xp22.3/Yp11.3 and by immunoglobulin heavychain translocations. Specifically, the PAR1 deletion was shown to be adjacent to the CSF2RA and CRFL2 genes. Array-based comparative genomic hybridization uncovered that the PAR1 deletion resulted in a rearrangement between first non-coding exon of P2RY8 and the entire coding region of CRLF2.
45 P2RY8 encodes a purinergic receptor that is expressed highly in a variety of tissues; indeed, this fusion results in higher CRFL2 expression. 48 Moreover, CRLF2 overexpression has also been seen in B-ALL cases due to IGH@-CRLF2 fusion. 43, 46 These rearrangements are fairly rare in non-DS-ALL, but common in DS-ALL with rates of~5% and 50%, respectively. Finally, a point mutation in CRLF2 resulting in F232C was also identified in 9% of DS-ALL patients and 21% of Table 2 . Clinical issues facing patients with DS-ALL
Issues Potential solutions
Unique toxicity profiles Treatment protocols modified for DS-ALL and universal supportive care guidelines are needed DS patients are not included in most studies for new agents for concern of higher toxicity Inclusion of DS patients should be considered in studies of novel agents, such as immunotherapy and JAK inhibitors. The latter may be especially interesting considering the role of JAK2 in the pathogenesis of DS-ALL Inferior outcome in DS-ALL compared with non-DS-ALL owing to higher relapse rate, which is at least partly attributed to physician's lack of adherence Optimizing protocol and encourage physicians adherence to study Abbreviations: ALL, acute lymphoblastic leukemia; DS, Down syndrome.
Biology and therapy of DS-ALL P Lee et al adult B-ALL patients who overexpress CRLF2. 43, 47 In a cytokinedeprived environment, this mutation alone does not necessarily increase cell survival capability; however, it was found to confer constitutive STAT5 (signal transducer and activator of transcription 5) phosphorylation in Ba/F3 cells and, in the presence of exogenous wild-type Jak2, increased growth of cells 15-fold compared with cells with wild-type CRLF2. 43 It is also noteworthy that the CRLF2 abnormality was seen in nearly 50% of cases of Ph-like ALL, with more than half of these also harboring JAK1/JAK2 mutations. 49 Thus, while CRLF2 rearrangement and overexpression tends to be the typical genetic alteration involved in DS-ALL, other mechanisms may ultimately contribute to same phenotype.
JAK2 mutations
As JAK-STAT signaling has an important role in B lymphopoiesis, several studies have not surprisingly revealed a role for JAK2 mutations in the etiology of ALL, particularly DS-ALL. Mutations that lead to activated JAK2 signaling include a novel deletion of five amino acids (JAK2ΔIREED) within the JH2 pseudokinase domain 50 and specific mutations in the R683 residue. In one study, 16 of 88 patients with DS-ALL harbored R683 mutations in bone marrow specimens, whereas none of the other 72 samples had any other JAK2 exon 16 mutations. 51 Of the missense mutations found in these 16 patients, 8 were R683G, 5 were R683S, 1 was R683K and 2 were large insertions before R683. This study confirmed that the R683 mutants led to constitutive phosphorylation of JAK2 and STAT5 and conferred cytokine-independent proliferation to Ba/F3/EpoR and Ba/F3/TpoR cells. Other studies reported a similar 20% incidence of R683 JAK2 mutations in independent cohorts of pediatric DS-ALL patients. 40, 52 It should be noted that aside from one R683K mutation, 51 all the R683 mutations replace the basic arginine with a neutral amino acid. This alteration may affect the interdomain interactions with the C-terminal kinase domain, resulting in constitutive JAK2 activation.
V617F mutations in JAK2 are very common in the myeloproliferative neoplasms, 53 whereas R683 mutations are never seen in this disease. Why are the V617F and R683 mutations restricted to the MPNs and B-ALL, respectively? The R683 and V617 residues both lie in the JAK2 pseudokinase domain, but on different highly conserved sites. 54 The DS-ALL mutations are predicted to affect the interactions with the C-terminal kinase domain, resulting in constitutive JAK2 activation, similar to the V617F mutation in the MPNs. Moreover, it is thought that both V617 and R683 mutations disrupt the interaction of the JAK2 pseudokinase domain with the JH1/JH2 domains, thereby reducing the intrinsic negative regulatory activity. However, the mechanism behind the selectivity of these mutations in AML vs ALL is still poorly understood. One report has described two structural hotspots in the JAK2 pseudokinase domain containing either V617 (hotspot I) or R683 (hotspot II). The authors postulate that mutations in these hotspots, in addition to activating JAK2, may alter the recruitment to different signaling complexes, thereby providing a potential mechanism behind the genotype-phenotype specificity of JAK2 pseudokinase mutations. 55 Cooperation between JAK2 and CRLF2 Several studies have reported an association between aberrant CRLF2 expression and JAK2 mutations in both B-ALL and Similarly, it has been found that gain-of-function IL-7R mutations allow for dimerization with CRLF2 and cytokine-independent growth of Ba/F3 cells; these heterodimers are more sensitive to signaling by TSLP relative to those with wild-type IL-7R (denoted by bolded line). However, despite the prevalence of these driver mutations, many cases of DS-ALL occur without this combination of events. Moreover, other changes, such as deletions in PAX5 and IKZF, are involved in the pathogenesis of DS-ALL. Of note, the latter two events were needed in combination with CRLF2 overexpression and a JAK2-activating mutation for development of an animal model of DS-ALL. 35 These genetic alterations exhibit an enormous variability in both nature and frequency, underscoring the genetic complexity of DS-ALL.
DS-ALL. 43, [45] [46] [47] While JAK2 mutations are most commonly found in the R683 pseudokinase domain, mutations have also been observed in the JAK2 kinase domain (T875N and G861W) and the JAK1 pseudokinase domain (V658F, the corresponding to the V617 residue of JAK2). 45 In one study of a validation cohort of 53 DS-ALL cases, 20 harbored the PAR1 deletion resulting in CRLF2 rearrangement; 8 of the 53 patients also harbored a JAK2 mutation, whereas the JAK2 mutation was only observed once in subjects without the PAR1 deletion. 45 A different study from the International Berlin-Frankfurt-Muenster study group found that 10 out of the 10 DS-ALL samples with JAK2 R683 mutations also exhibited CRLF2 overexpression. 43 These data suggest a tight association between the occurrence of CRLF2 and JAK2 genetic alterations in DS-ALL etiology.
This high incidence of co-occurrence of the two events suggests that there is cooperation between CRLF2 and JAK2 alterations. Indeed, while expression of P2RY8-CRLF2 or JAK2 mutants alone in Ba/F3-IL-7R cells was insufficient to induce cytokine-independent growth, expression of both led to constitutive JAK-STAT signaling and cytokine independence. 45 Similar experiments were performed in Ba/F3 cells that express CRLF2 by coexpression of wild-type JAK2 or the R683S mutant. Although JAK2 R683S expression allowed for cytokine-independent growth, the effect was significantly amplified when R683S was coexpressed with CRLF2. 43 The F232C CRLF2 mutation similarly cooperated with JAK2 mutations in promoting cytokine-independent growth. 43, 47 However, despite the prevalence of CRLF2 overexpression and JAK2-activating mutations in DS-ALL, many still lack these wellcharacterized lesions, implying that there are other components of the disease that still require further study, several of which are described below.
In addition to JAK mutations driving JAK/STAT signaling in malignant B cells, a recent study identified mutations in the interleukin-7 receptor in patients with B-and T-ALL. 56 In B-ALL the mutations were associated with aberrant CRLF2 activation, forming a functional receptor for TSLP. The IL-7R mutations included a S185C mutation in the extracellular domain or, more commonly, an in-frame indel in the transmembrane domain. These mutations were found to confer constitutive activation of IL-7R and allow for cytokine-independent growth of Ba/F3 cells in conjunction with CRLF2 overexpression. Furthermore, the S185C mutations sensitizes the cells to TSLP; the addition of TSLP at doses that did not support growth of Ba/F3 cells expressing wild-type IL-7R doubled the growth rate of Ba/F3 cells expressing the S185C mutant. 56 Not all cases of CRLF abnormalities are associated with JAK2 mutations. One recent study reported the identification of mutations in NRAS or KRAS in 15 of 42 DS-ALL cases, which is similar to the incidence of JAK2 or P2RY8-CRLF2 fusions. 57 The RAS mutations were mutually exclusive with JAK2 mutations. Interestingly, in two of three cases of relapsed patients, it was found that the JAK2-or PTPN11-mutated subclones had disappeared after standard chemotherapy and were replaced by RAS mutant subclones. This observation supports a model of mutual exclusivity of RAS and JAK2 mutations in this malignancy. The interplay between these multiple signaling mechanisms highlights both the complexity and the importance of the CRLF2-JAK2 axis in promoting leukemic potential.
CHROMOSOME 21 CONTRIBUTIONS TO DS-ALL
Multiple mouse models of DS, including the Ts65Dn and Ts1Rhr strains that are trisomic for 104 and 31 orthologs of Hsa21 genes, respectively, develop a progressive myeloproliferative disorder characterized by increased megakaryopoiesis and thrombocytosis. 58, 59 Moreover, combining the partial trisomy of the Ts1Rhr mice with a Gata1 mutation and an activating mutation in MPL leads to an aggressive DS-AMKL-like phenotype in vivo. 59 Recently, the validity of using mouse models to study leukemia in humans with DS was extended by a demonstration that mouse models of DS also develop B-ALL. 35 The disease required not only a JAK2 mutation and CRLF2 overexpression but also heterozygous loss of Pax5 and expression of a dominant-negative Ikzf isoform in the Ts1Rhr bone marrow. These findings reveal DS-ALL is indeed a complex genetic disorder.
While trisomy 21 is clearly associated with leukemia, the specific gene(s) on this chromosome that promotes B-ALL when present in three copies remains unclear. Two recent studies have implicated specific Hsa21 genes, HMGN1 and DYRK1A, in lymphopoiesis and the disease process. 35, 36 The nucleosome remodeling protein HMGN1 To uncover how trisomy 21 promotes lymphoid neoplasia, Lane et al. 35 carefully analyzed lymphopoiesis in the Ts1Rhr mouse model. First, they compared the ratio of B cells that fell into the different Hardy fractions, which were described in 1991 as a way to classify B-cell precursors based on the expression of cell surface proteins. 60 They discovered that there was an accumulation of B cells in the less mature Hardy A fraction with concomitant reductions in the more mature B and C fractions in the Ts1Rhr mice. 35 There was also an overall reduction in B-cell numbers. Next, they investigated the colony-forming activity of B-cell progenitors and made the surprising observation that pre-B cells from the trisomic animals had the ability to replate for at least 10 generations, despite the reduction in their overall numbers. This replating phenotype indicates that the presence of three alleles of 1 (or more) of the 31 trisomic genes confers progenitor B-cell self-renewal. Finally, as polysomy 21 is a common aneuploidy in BCR-ABL-rearranged B-ALL, they investigated cooperation between trisomy 21 and BCR-ABL in vivo. While transplantation of control disomic bone marrow expressing p210 BCR-ABL led to B-ALL in recipients, mice that were engrafted with Ts65Dn bone marrow cells expressing BCR-ABL succumbed to B-ALL with a shorter latency and increased penetrance. This result confirms that triplication of one or more of the trisomic genes in Ts65Dn mice has proleukemic activity.
Several lines of evidence suggest that Hmgn1, a nucleosome binding protein that has been implicated in histone H3 modifications, 61 is one of the critical trisomic genes that alters B-cell development in Ts1Rhr mice. First, Ts1Rhr pre-B cells that were depleted for Hmgn1 failed to replate in vitro, indicating that persistent expression of the gene is needed for self-renewal. 35 Second, overexpression of HMGN1 in Ba/F3 cells suppressed H3K27me3 levels. This is consistent with the global reduction in H3K27me3 observed in the trisomic pre-B colonies. Third, overexpression of HMGN1 alone was sufficient to confer a more aggressive BCR-ABL induced B-ALL to euploid progenitors. Taken together, this study points to HMGN1 as a critical B-cell leukemiapromoting gene on Hsa21. As overexpression of HMGN1 in Ba/F3 cells suppressed trimethylation of H3K27, Lane et al. 35 hypothesized that increasing H3K27me3 levels in Ts1Rhr progenitors might reverse the effect of trisomy. As predicted, GSK-J4, a smallmolecule inhibitor of H3K27 demethylases, impaired Ts1Rhr B-cell colony formation and replating activity. Future research with GSK-J4 and analogs with better bioavailability will shed more light on the potential for targeting H3K27 methylation in this disease.
Interestingly, it has been reported that trisomy 21 in human fetal liver is associated with impaired B-cell development as evidenced by a reduction in committed B-lineage progenitors, as well as a decrease in the ability of HSCs, lymphoid-primed multipotent progenitors and early lymphoid progenitors to develop into mature B cells. 62 This reduction in pre-pro-B cells and pro-B cells parallels the reductions in B-cell fractions in the Ts1Rhr animals. However, the extent to which the in vitro expansion of Ts1Rhr pre-B cells recapitulates preleukemia events in humans remains to be determined.
The dual-specificity kinase DYRK1A One of the major players in the neuronal pathogenesis of DS is DYRK1A, transcribed from the DSCR of chromosome 21.
63
A member of the CMGC superfamily, DYRK1A has been well characterized in various tissues, particularly neurological models, with roles including cell proliferation and differentiation, 64 RNA splicing 65 and apoptosis. 66 DYRK1A was not studied in hematopoiesis until an AMKL-promoting role for the kinase was discovered by virtue of its dysregulation of nuclear factor of activated T-cell activity. 59 While this inhibition of nuclear factor of activated T-cell signaling by DYRK1A has been linked to lower incidence of cancers in adults with DS, 67 the data in this former study suggest that increased nuclear factor of activated T-cell dysregulation promotes AMKL in children with DS, thereby providing evidence for DYRK1A having both cancer-promoting and cancer-inhibitory activities.
DYRK1A may have a role in the promotion of ALL, but, likely through a pathway different from that in AMKL, as Dyrk1a was recently shown to be essential for lymphoid, but not myeloid, cell development. 36 Ablation of Dyrk1a in the proliferative stages of pre-B and pre-T cells led to a transcriptional upregulation of cell cycle-promoting genes. However, while these cells appeared to be in the S-G2-M cycling state, there was a decrease in total cell number and an inability of pre-B colonies to proliferate ex vivo. There have been previous studies suggesting a significant role for DYRK1A in cell cycle regulation in other tissues, such as phosphorylation of Lin52 (S28) and consequential assembly of the cell cycle regulatory DREAM complex 68 or phosphorylation and stabilization of p27. 69 Within developing lymphocytes, DYRK1A phosphorylates cyclin D3 on T283, a highly conserved phosphodegron site among D-type cyclins. 36 Furthermore, degradation of phosphorylated cyclin D3 was associated with repression of E2F target genes. This finding complements a previous study, which showed that DYRK1A phosphorylation of cyclin D1 on the homologous T286 induced G 0 cell cycle exit and differentiation of fibroblasts. 70 Thus, by negatively regulating cyclin D3 stability, DYRK1A has a major role shifting lymphocytes from proliferation to quiescence. Despite the fact that Dyrk1a-deficient cells fail to enter quiescence, they did not accumulate in the animal. 36 Rather, large pre-B cells lacking Dyrk1a completed fewer cell divisions than control cells, indicating that DYRK1A has additional roles in cell growth. The requirement for Dyrk1a in lymphopoiesis suggests that it may be a novel target for therapeutic intervention. Importantly, loss of Dyrk1a had no effect on the myeloid lineages, further supporting the potential of DYRK1A inhibition as a targeted therapy for ALL.
OTHER GENETIC ALTERATIONS
In addition to the previously discussed genetic alterations associated with DS-ALL, there are several other genetic events that have been observed. Among these, deletions of IKZF1 and PAX5 are often cited, both of which are prevalent in non-DS-ALL. 39, 71 While loss of IKZF1 alone does not lead to the development of B-ALL, in the context of BCR-ABL1, IKZF1 haploinsufficiency reduced the latency in the development of B-ALL in transgenic mice. 37 Similarly, deletion of IKZF1 has been observed in~75% of BCR-ABL1-positive B-ALL cases. In murine models, it has been shown that the dominant-negative isoform tends to have a more severe leukemic phenotype, although haploinsufficiency accelerates the development of leukemia. 37 Thus, despite the different effects of these deletions, both cases are strongly implicated in hematologic neoplasia. In DS-ALL patients, the frequency of IKZF1 deletions (26-35%) is comparable to high-risk non-DS-ALL patients (29%) based on independent cohorts from the Dutch Childhood Oncology Group and UK trials. 39 Interestingly, compared with B-ALL patients, DS-ALL patients have a significantly lower incidence of combined IKZF1 deletion and JAK2 mutations, which provides further evidence that genetic patterns causative of DS-ALL differ significantly from non-DS-ALL. PAX5 is another gene involved in B-cell development that has been implicated in DS-ALL. Analysis of the Dutch Child Oncology Group cohorts revealed deletions in PAX5 in 12% of DS-ALL patients, and the event was not mutually exclusive to IKZF1 deletions.
iAMP21
Another causative genetic event in ALL that reflects the contribution of trisomy 21 is an intrachromosomal amplification of chromosome 21 (iAMP21), which has been reported in 2% of pediatric ALL.
72 iAMP21 rarely arises from a germline Robertsonian translocation, rob(15;21)(q10,q10)c, or more commonly is sporadically initiated by breakage-fusion-bridge repair cycles. Both of these events display evidence of chromothripsis as an inciting mechanism 73 and may result in duplications of the abnormal chromosome. While rob(15;21)c only accounts for 0.5-1% of all Robertsonian translocations, patients with this chromosomal abnormality have a~2700-fold increased risk in developing iAMP21-ALL. 73 Genetic analysis of patients with iAMP21 has revealed several interesting patterns. For example, one study showed that while RUNX1 is often found in the amplified region of patients with iAMP21, and RUNX1 translocations with ETV6 are commonly associated with ALL, RUNX1 mutations are generally not seen in iAMP21. 74 Similarly, JAK mutations were seen in none of the 15 iAMP ALL patients in that study. Additionally, of 94 samples from iAMP21 patients, the group observed IKZF deletions (16%), PAX5 deletions (8%), CDKN2A deletions (13%), ETV6 deletions (15%), RB1 deletions (13%), gain of X-chromosome (20%) and P2RY8-CRLF2 fusion (17%). Moreover, although iAMP21 has always been characterized in patients with non-DS-ALL, many of the genes amplified are in the region of chromosome 21 that has been implicated in the phenotypes associated with DS. These include RUNX1 and miR-802. Another study that analyzed a minimal iAMP region revealed that that the most highly amplified regions of chromosome 21 includes RUNX1, DYRK1A and ETS2. 73 Certain genetic elements that are characteristic of DS-ALL are also seen in similar frequency in iAMP21-ALL, most notably gain of X-chromosome (20% in iAMP21-ALL, 24% in DS-ALL) and P2RY8-CRLF2 fusion (17% in iAMP21-ALL, 22% in DS-ALL). 74 Nevertheless, there are still significant differences, such as the lack of JAK mutations in iAMP21, despite the high rate of occurrence in DS-ALL. Thus, the differences between iAMP21-ALL and DS-ALL underscore the complexity of genetic events involved in B-cell leukemia.
CONCLUSIONS AND FUTURE DIRECTIONS
DS-ALL is a unique entity that is characterized by a largely distinct subset of mutations, including trisomy 21, high rates of CRLF2 overexpression and JAK2 mutations. Although the overall responses are similar to children without DS, patients with DS-ALL are at higher risk for relapse and for severe side effects as a consequence of their hypersensitivity to conventional chemotherapy. In contrast to DS-AMKL, which has a well-defined genetic basis of GATA1 mutations on the X chromosome, 10 the pathogenesis of DS-ALL is far more complex. Development of an animal model of DS-ALL required four events beyond trisomy: CRLF2 overexpression, a JAK2 mutation and losses of Pax5 and Ikzf. 35 There are many questions to consider as we move towards novel therapies for DS-ALL. First, what are the specific genes that contribute to the leukemia predisposition? The study by Lane et al. 35 compellingly demonstrated that HMNG1 is a strong candidate proleukemia gene, whereas the study by Thompson et al. 36 provided evidence that DYRK1A is at least required for B-ALL. There are 29 other candidate genes in the Ts1Rhr model and well over 100 others from Hsa21 that need to be considered. With the advent of CRISPR technology, it is likely that experiments to identify the genes in an unbiased manner will more quickly forward. Second, why is there a strong link between JAK2 mutations and CRLF2 alterations? Third, what does the future hold with respect to novel and more effective therapies for DS-ALL? Studies to test JAK inhibitors, chimeric antigen receptor T cells and immunomodulatory agents that are ongoing or planned will certainly advance the field. Given the multitude of health issues that individuals with DS face, we should strive to develop less toxic and more efficacious treatments.
